Ascendis Pharma ASASND -1.87%37 Graham Number is $44.64 as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review. Among 252 Biotechnology companies, Ascendis Pharma AS ranks worse than 89.68% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-12), the stock price of Ascendis Pharma AS is $270.51. Ascendis Pharma AS's graham number for the quarter that ended in Mar. 2026 was $44.64. Therefore, Ascendis Pharma AS's Price to Graham Number ratio for today is 6.06.
The historical rank and industry rank for Ascendis Pharma AS's Graham Number or its related term are showing as below:
ASND'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6.06
Current: 6.06
During the past 13 years, the highest Price to Graham Number ratio of Ascendis Pharma AS was 6.06. The lowest was 0.00. And the median was 0.00.
ASND's Price-to-Graham-Number is ranked worse than 89.68% of 252
companies
in the Biotechnology industry
Industry Median: 1.815
vs ASND: 6.06
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Ascendis Pharma AS (NAS:ASND) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Ascendis Pharma AS's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
270.51
/
44.64
=
6.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Ascendis Pharma AS Graham Number Related Terms
Ascendis Pharma AS Graham Number Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs JAZZ, BBIO, EXEL: Graham Number Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (ASND) has a Graham Number of $44.64 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #226 out of 252 companies in the Biotechnology industry, placing it in the top 89.7%.
Is Ascendis Pharma AS's Graham Number too high?
Ascendis Pharma AS's current Graham Number is $44.64. The Biotechnology industry median Graham Number is 1.82. Ascendis Pharma AS's value of $44.64 is 2359.5% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #226 out of 252 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Graham Number compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #226 out of 252 companies for Graham Number. This places Ascendis Pharma AS in the lower half of its industry. The industry median Graham Number is 1.82. Ascendis Pharma AS's value of $44.64 is 2359.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.82, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Graham Number of $44.64 is 2359.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Graham Number is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Graham Number is $44.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Graham Number of $44.64. The current Graham Number is $44.64 and 2359.5% above the Biotechnology industry median of 1.82. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Graham Number is $44.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for ASND
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
